ARTICLE | Finance
Familiarity breeds opportunity
Why HBM Partners led $50M round for pediatric oncology play Y-mAbs
October 28, 2017 12:14 AM UTC
Confidence in Y-mAbs Therapeutics Inc.’s management team and late-stage programs in pediatric oncology where treatment options are sparse drove HBM Partners' decision to lead the company's $50 million venture round.
Undisclosed existing investors also participated in the financing, announced on Oct. 24. The biotech had previously raised $37 million in two venture rounds since its founding in 2014. ...
BCIQ Company Profiles